Cure My Disease

Don't miss your cure!

 Log in / Sign up

Selective cell removal may tame stem cell Transplant's dangerous side effect

NCT ID NCT07660783

Not yet recruiting Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood disorders such as bone marrow failure, sickle cell disease, or immune deficiencies who need a stem cell transplant. Participants receive chemotherapy and low-dose radiation before the specially processed donor stem cells are infused.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD34-enriched, CD45RA-depleted donor stem cells
What this could lead to
If successful, this approach could reduce severe graft-versus-host disease after stem cell transplant for non-malignant blood disorders, improving safety and quality of life.
What could go wrong
This is a small, early-phase trial. The special graft may not prevent GVHD as hoped, and risks like infection or graft failure remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE CYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Marrow Failure Disorders bone marrow failure syndrome disease Evans syndrome hemoglobinopathy hemophagocytic syndrome immune system disorder inborn error of immunity inherited hemoglobinopathy Lymphohistiocytosis, Hemophagocytic Primary Immunodeficiency Diseases graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE CYTOPENIA BONE MARROW FAILURE HEMOGLOBINOPATHIES HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IMMUNE DYSREGULATION NON MALIGNANT DISORDERS PRIMARY IMMUNE DEFICIENCY (PID)

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.